Compare PJT & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PJT | LQDA |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.8B |
| IPO Year | 2015 | 2020 |
| Metric | PJT | LQDA |
|---|---|---|
| Price | $152.17 | $45.19 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $161.11 | $54.38 |
| AVG Volume (30 Days) | 409.1K | ★ 5.3M |
| Earning Date | 11-03-2026 | 11-10-2026 |
| Dividend Yield | ★ 0.67% | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | N/A | ★ 1.26 |
| Revenue | ★ $1,713,671,000.00 | $158,320,000.00 |
| Revenue This Year | $8.41 | $357.27 |
| Revenue Next Year | $13.42 | $1.34 |
| P/E Ratio | ★ $23.03 | $36.28 |
| Revenue Growth | 14.77 | ★ 1031.18 |
| 52 Week Low | $127.73 | $22.22 |
| 52 Week High | $195.62 | $93.61 |
| Indicator | PJT | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 61.15 | 51.59 |
| Support Level | $144.58 | $35.00 |
| Resistance Level | $163.37 | $46.67 |
| Average True Range (ATR) | 4.42 | 2.99 |
| MACD | 2.60 | 2.79 |
| Stochastic Oscillator | 81.71 | 90.56 |
PJT Partners Inc is an advisory-focused investment bank that offers a portfolio of advisory services designed to help its clients achieve their strategic objectives. The company delivers a range of strategic advisory, capital markets advisory, restructuring and special situations, and shareholder advisory services to corporations, financial sponsors, institutional investors, and governments around the world. It also provides private fund advisory and fundraising services for alternative investment strategies, including private equity, real estate, hedge funds, and private credit. The company generates its revenue from advisory fees, placement services, and others. Geographically, it generates maximum revenue from the United States, followed by the United Kingdom and other markets.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.